An ultrasonically responsive nanocomposite material, its preparation method and its application
By using ferrocene side chains in ultrasound-responsive nanocomposites to release ferrous ions under ultrasound, catalyzing the Fenton reaction, and destroying the mitochondria and DNA of drug-resistant tumor cells, the problem of cisplatin resistance is solved, and precise and efficient elimination of tumor cells is achieved.
Patent Information
- Application Number
- CN202611315034.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-08-27
- Publication Date
- 2026-11-17
AI Technical Summary
Existing platinum-based drugs, such as cisplatin, have the problem of tumor cell resistance when treating cancer, resulting in limited treatment efficacy and the potential to trigger breakthrough proliferation and metastasis of tumors.
Develop an ultrasound-responsive nanocomposite material containing copolymers and platinum-based drugs. Under ultrasound stimulation, the ferrocene side chains break down to release ferrous ions, which catalyze the Fenton reaction to generate a ROS storm, destroying mitochondria and activating ferroptosis and apoptosis pathways, thereby reversing drug resistance.
It significantly improved the killing ability against tumor cells, reversed cisplatin resistance, and achieved precise and efficient elimination of drug-resistant tumor cells without affecting normal tissues.
Smart Images

Figure CN123107074A_ABST
Abstract
Description
Technical Field
[0001] This application relates to the field of pharmaceutical technology, and in particular to an ultrasonically responsive nanocomposite material, its preparation method, and its application. Background Technology
[0002] Platinum-based chemotherapy is a first-line treatment for many cancers in clinical practice. Cisplatin (CDDP), as a first-generation platinum-based anticancer drug, is widely used in the clinical treatment of lung cancer, ovarian cancer, head and neck cancer, and other cancers. Cisplatin effectively inhibits the malignant proliferation of tumor cells by disrupting DNA function, inhibiting cell replication, and ultimately activating the apoptosis pathway. However, platinum-based drugs such as cisplatin have limited ability to kill tumor cells. Long-term, phased administration of these drugs can easily lead to drug resistance in tumor cells, causing breakthrough proliferation and metastasis of tumors. Therefore, addressing cellular resistance to platinum-based drugs is currently one of the key research focuses. Summary of the Invention
[0003] In view of this, this application provides an ultrasound-responsive nanocomposite material, its preparation method and its application. The ultrasound-responsive nanocomposite material provided by this application significantly improves the killing ability of cisplatin against tumor cells, reverses cisplatin resistance, and improves the precise and efficient removal of tumor cells.
[0004] This application provides a copolymer of formula (I):
[0005] Formula (I);
[0006] In equation (I), R1 is or R2 is or R3 represents H, CH3, , , , , or ;
[0007] q, r, and s are independently selected from integers from 1 to 4;
[0008] n and m are the degree of polymerization;
[0009] x+y+z=m, 0<x<m, 0<y<m, 0≤z<m.
[0010] The copolymers provided in this application can be block copolymers or random copolymers. When z=0, it is a diblock copolymer or a random copolymer of two repeating units. When z is not equal to 0, it is a triblock copolymer or a random copolymer of three repeating units.
[0011] In the structure of equation (I), R1 is or Where q and r are independently selected from integers 1 to 4, for example 1, 2, 3 or 4; preferably, R1 has the following structure:
[0012] , , or .
[0013] In the structure of equation (I), R2 is or Where s is selected from an integer from 1 to 4, for example, 1, 2, 3 or 4; preferably, R2 has the following structure:
[0014] or .
[0015] In the structure of formula (I), R3 is H, CH3, , , , , or Preferably, R3 is H.
[0016] In the copolymer shown in formula (I), m is the degree of polymerization, which is preferably an integer between 10 and 100, more preferably an integer between 10 and 50, and most preferably an integer between 20 and 40. For example, m is 10, 20, 30, 40, or 50, etc.
[0017] In the copolymer shown in formula (I), n is the degree of polymerization, which is preferably an integer between 20 and 200, more preferably an integer between 60 and 120, and most preferably an integer between 100 and 120. For example, n is 60, 80, 100, 110, 120, 150, etc.
[0018] In the copolymer shown in formula (I), x + y + z = m, 0 < x < m, 0 < y < m, 0 ≤ z < m. Preferably, 0 < x < 2 / 3 m, 0 < y < 2 / 3 m, 0 ≤ z < 1 / 3 m. More preferably, 0 < x ≤ 1 / 2 m, 0 < y ≤ 1 / 2 m, 0 ≤ z < 1 / 3 m.
[0019] In some specific implementations, the copolymer shown in formula (I)
[0020] R1 is R2 is ;
[0021] z=0.
[0022] In some specific implementations, m is selected from an integer between 10 and 100;
[0023] The n is selected from an integer between 20 and 200;
[0024] 0<x<2 / 3m, 0<y<2 / 3m, 0≤z<1 / 3m.
[0025] In some specific implementations, the copolymer has the structure of formula (I-1):
[0026] Formula (I-1).
[0027] In some specific implementations, in equation (I-1), n is preferably an integer between 20 and 200, more preferably an integer between 60 and 120, and most preferably an integer between 100 and 120. For example, n is 60, 80, 100, 110, 120, 150, etc.
[0028] In some specific implementations, in equation (I-1), m is preferably an integer between 10 and 100, more preferably an integer between 10 and 50, and most preferably an integer between 20 and 40. For example, m is 10, 20, 30, 40, or 50, etc.
[0029] In some specific implementations, in equation (I-1), 0 < x < 2 / 3m and 0 < y < 2 / 3m. For example, x = 1 / 2m and y = 1 / 2m.
[0030] In some specific implementations, n=113, m=20, 30 or 40. When m=20, x=y=10; when m=30, x=y=15; when m=40, x=y=20.
[0031] The copolymer provided in this application contains ferrocene side chains, exhibiting ultrasonic responsiveness. Under ultrasonic stimulation, these chains break down and release ferrous ions. These ferrous ions catalyze a cascade Fenton reaction, triggering a reactive oxygen species (ROS) storm. The ROS storm first severely damages mitochondria—the cristae break down and disappear, the membrane potential (ΔΨm) decreases, and energy metabolism collapses. Simultaneously, intracellular glutathione (GSH) is significantly depleted, and lipid peroxides (LPO) surge. GSH depletion inhibits glutathione peroxidase 4 (GPX4) expression, while LPO accumulation directly initiates ferroptosis, thereby disrupting the expression of drug resistance glycoproteins (P-gp) and reversing drug resistance.
[0032] This application also provides a method for preparing copolymers having the structure of formula (I-1):
[0033] The amino-terminated polyethylene glycol and lysine N-carboxylic anhydride were subjected to a ring-opening polymerization reaction to obtain polyethylene glycol monomethyl ether-b-polylysine.
[0034] Ferrocene formate and polyethylene glycol monomethyl ether-b-polylysine were grafted together to obtain an intermediate product.
[0035] The succinic anhydride and the intermediate product were reacted to obtain a copolymer.
[0036] The reaction process is as follows:
[0037]
[0038] This application uses amino-terminated polyethylene glycol (mPEG-NH2) as an initiator to initiate the ring-opening polymerization of lysine N-carboxylic anhydride to obtain polyethylene glycol monomethyl ether-b-polylysine. In some specific implementations, the amino-terminated polyethylene glycol has a weight-average molecular weight of 1000-10000, preferably 2000-8000, and more preferably 3000-6000. This application does not have any special restrictions on the source of the amino-terminated polyethylene glycol; commercially available products are acceptable.
[0039] In some specific implementations, amino-terminated polyethylene glycol is preferably treated according to the following method:
[0040] The amino-terminated polyethylene glycol was mixed with a solvent and subjected to azeotropic dehydration. After removing the solvent under reduced pressure, dry amino-terminated polyethylene glycol was obtained.
[0041] In some specific implementations, the solvent is anhydrous toluene. In some specific implementations, the azeotropic dehydration temperature is 100℃~150℃, preferably 120℃~140℃, and the time is 1h~3h, preferably 1.5h~2.5h. In some specific implementations, the mass ratio of the amino-terminated polyethylene glycol to the volume of the solvent is 1.0 g~10.0 g: 300 mL~500 mL, preferably 3 g~8 g: 350 mL~450 mL.
[0042] This application uses lysine N-carboxylic anhydride as the polymerization monomer. In some specific implementations, lysine N-carboxylic anhydride is protected by a protecting group, including but not limited to N6-benzyloxycarbonyl-L-lysine intracyclic anhydride. When the lysine N-carboxylic anhydride is protected by a protecting group, this application also includes a deprotection step after ring-opening polymerization to obtain polyethylene glycol monomethyl ether-b-polylysine.
[0043] Taking N6-benzyloxycarbonyl-L-lysine intracyclic anhydride (Cbz-Lys NCA) as an example, a typical synthesis process is as follows:
[0044] Using amino-terminated polyethylene glycol (mPEG-NH2) as an initiator, ring-opening polymerization of N6-benzyloxycarbonyl-L-lysine intracyclic anhydride (Cbz-Lys NCA) was initiated to obtain polyethylene glycol monomethyl ether-b-poly(N-benzyloxycarbonyl-lysine) (mPEG-bP(Cbz-Lys)).
[0045] The polyethylene glycol monomethyl ether-b-poly(N-benzyloxycarbonyl-lysine) was deprotected to obtain polyethylene glycol monomethyl ether-b-polylysine (mPEG-b-PLys).
[0046] Specifically, this application first mixes mPEG-NH2 with a reaction solvent. After homogeneous mixing, it is then mixed with Cbz-Lys NCA under nitrogen protection to carry out a ring-opening polymerization reaction. In some specific implementations, the reaction solvent includes, but is not limited to, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), tetrahydrofuran (THF), and dichloromethane (DCM). In some specific implementations, the ring-opening polymerization reaction is carried out at a temperature of 15°C to 35°C, preferably 20°C to 30°C, for a time of 1 day to 5 days, preferably 2 days to 4 days. After the reaction is complete, the resulting polymer solution is slowly added dropwise to 8 to 10 times its volume of ice-cold diethyl ether, allowing precipitation to obtain mPEG-bP(Cbz-Lys).
[0047] After obtaining mPEG-bP(Cbz-Lys), it is deprotected to obtain mPEG-b-Plys. Specifically, this application mixes mPEG-bP(Cbz-Lys) with trifluoroacetic acid (TFA), then adds HBr / AcOH, and removes the protecting group after the reaction. In some specific implementations, the reaction temperature is 15 ℃~35 ℃, preferably 20 ℃~30 ℃, and the time is 1 h~3 h, preferably 1.5 h~2.5 h. After the reaction is complete, the resulting solution is slowly added dropwise to pre-cooled diethyl ether to induce product precipitation. The precipitate is separated by centrifugation, redissolved, dialyzed, and freeze-dried to obtain mPEG-b-Plys.
[0048] After obtaining mPEG-b-Plys, ferrocene formate and mPEG-b-Plys are subjected to a grafting reaction to obtain an intermediate product grafted with ferrocene. Specifically, in this application, ferrocene formate and mPEG-b-Plys are mixed in a reaction solvent, and then a condensing agent and a catalyst are added to carry out the reaction, grafting ferrocene groups onto mPEG-b-Plys. In some specific implementations, the molar ratio of amino groups in ferrocene formate and mPEG-b-Plys is i:1, where i has the meaning as described above, which will not be repeated here.
[0049] In this application, the preferred mass ratio of mPEG-b-Plys, condensing agent, and catalyst is 0.5~2:0.1~0.5:0.1~0.5, more preferably 1~1.5:0.2~0.4:0.2~0.4. In some specific implementations, the condensing agent includes, but is not limited to, 1,3-diisopropylcarbodiimide (DIC), dicyclohexylcarbodiimide (DCC), and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC); the catalyst is an organic base, including but not limited to 4-dimethylaminopyridine (DMAP) and 1-hydroxybenzotriazole (HOBt). In some specific implementations, the reaction solvent includes, but is not limited to, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), and dichloromethane (DCM). In some specific implementations, the reaction temperature is 15℃~35℃, preferably 20℃~30℃, and the reaction time is 1 day~5 days, preferably 2 days~4 days. After the reaction is complete, the resulting reaction solution is precipitated in ice-cold diethyl ether. The resulting white precipitate is then vacuum dried, reconstituted, and dialyzed to obtain an intermediate product grafted with ferrocene.
[0050] After obtaining the ferrocene-grafted intermediate, it is reacted with succinic anhydride to obtain a copolymer having the structure of formula (I) (where z is 0). In some specific implementations, the mass ratio of the succinic anhydride to the amino group of the ferrocene-grafted intermediate is 1-3:1, preferably 2:1, so that the succinic anhydride completely caps the amino group of the ferrocene-grafted intermediate to form a terminal carboxyl group. Specifically, in this application, the ferrocene-grafted intermediate is mixed with succinic anhydride after adjusting the pH value, and the reaction is carried out under conditions that maintain a constant pH value. In this application, the ferrocene-grafted intermediate is first dissolved in water, and then the pH value of the ferrocene-grafted intermediate is adjusted to 8-9, more preferably 8.6. In some specific implementations, 1.0 mol L is preferred. −1The pH of the intermediate grafted with ferrocene is adjusted using an aqueous sodium hydroxide solution. In some specific implementations, the pH is kept constant at 8-9 during the reaction, the reaction temperature is 15-35°C, preferably 20-30°C, and the reaction time is 5-20 h, preferably 6-15 h.
[0051] When z is not 0, the corresponding amino acid monomer raw material can be added for copolymerization during the ring-opening polymerization reaction of the above amino-terminated polyethylene glycol and lysine N-carboxylic anhydride. There are no special restrictions in this application.
[0052] Other polymers can be synthesized by referring to the method described above, and will not be repeated here.
[0053] This application also provides an ultrasonically responsive nanocomposite material, comprising: a copolymer of formula (I) and a platinum-containing drug;
[0054] Formula (I);
[0055] In equation (I), R1 is or R2 is or R3 represents H, CH3, , , , , or ;
[0056] q, r, and s are independently selected from integers from 1 to 4;
[0057] n and m are the degree of polymerization;
[0058] x+y+z=m, 0<x<m, 0<y<m, 0≤z<m.
[0059] The ultrasonically responsive nanocomposite material provided in this application includes the copolymer shown in formula (I), which is as described in the above scheme and will not be repeated here.
[0060] The ultrasonically responsive nanocomposite material provided in this application includes a platinum-containing drug, which coordinates and self-assembles with the copolymer shown in formula (I) to form a nanomedicine. This application does not impose any special limitations on the platinum-containing drug, including but not limited to cisplatin, carboplatin, oxaliplatin, transplatin, and nedaplatin, and may contain one or more of these. When multiple drugs are combined, this application does not impose any special limitations on the proportions of each specific substance. In some specific implementations, the platinum-containing drug is preferably cisplatin.
[0061] In some specific implementations, the molar ratio of the carboxyl group of the copolymer to the platinum-containing drug is 0.1 to 10:1, for example, 1:1, 0.5:1, 2:1, 3:1, 4:1, etc., preferably 1:1.
[0062] The ultrasonically responsive nanomedicine provided in this application has a size of 50 nm to 150 nm, preferably 60 nm to 130 nm.
[0063] In the ultrasound-responsive nanomedicine provided in this application, the copolymer shown in Formula (I) contains ferrocene side chains, exhibiting ultrasound responsiveness. Under ultrasound, it breaks down and directionally releases ferrous ions. These ferrous ions catalyze a highly efficient Fenton reaction, triggering a reactive oxygen species (ROS) storm. The ROS storm first severely damages mitochondria—the mitochondrial network fragments, membrane potential (ΔΨm) decreases, and energy metabolism collapses. Simultaneously, intracellular glutathione (GSH) is massively depleted, and lipid peroxides (LPO) surge. GSH depletion inhibits glutathione peroxidase 4 (GPX4) expression, while LPO accumulation directly initiates ferroptosis. The simultaneous downregulation of P-glycoprotein (P-gp) disrupts the cisplatin efflux pathway, significantly reversing drug resistance. Simultaneously, with continued ultrasound, the polymer completely disintegrates, releasing active cisplatin; cisplatin rapidly cross-links with DNA, activating the apoptosis pathway. At the same time, ROS and DNA damage signals synergistically amplify autophagy, forming a triple attack network of ferroptosis-apoptosis-autophagy, achieving precise and efficient elimination of drug-resistant tumor cells.
[0064] This application also provides a method for preparing an ultrasonically responsive nanocomposite material, comprising the following steps:
[0065] A copolymer having the structure of formula (I) was subjected to a coordination reaction with a platinum-containing drug to obtain an ultrasonically responsive nanocomposite material.
[0066] Formula (I);
[0067] In equation (I), R1 is or R2 is R3 represents H, CH3, , , , , or ;
[0068] q, r, and s are independently selected from integers from 1 to 4;
[0069] n and m are the degree of polymerization;
[0070] x+y+z=m, 0<x<m, 0<y<m, 0≤z<m.
[0071] This application describes a coordination reaction between a copolymer having the structure of formula (I) and a platinum-containing drug. Taking a copolymer having the structure of formula (I-1) as an example, the reaction process is as follows:
[0072]
[0073] This application does not impose any special restrictions on the preparation method of the copolymer having the structure of formula (I), and it can be prepared by referring to the method of copolymer having the structure of formula (I-1) described above.
[0074] This application first dissolves the copolymer having the structure of formula (I), then dialyzes it, and finally concentrates it by ultrafiltration to obtain nanoparticles. Specifically, this application dissolves the copolymer having the structure of formula (I) using solvents including but not limited to N,N-dimethylformamide (DMF), tetrahydrofuran (THF), acetone, etc., and then dialyzes it in PBS solution using a constant flow pump for 3 h to 8 h, preferably 6 h. During the dialysis process, the PBS solution is changed once every hour. Finally, the solution is concentrated by ultrafiltration and brought to volume with PBS solution to obtain a solution containing nanoparticles of the copolymer having the structure of formula (I).
[0075] After obtaining a solution containing nanoparticles of a copolymer having the structure of formula (I), it is mixed with a platinum-containing drug, reacted, and then dialyzed to obtain an ultrasound-responsive nanomedicine. In some specific implementations, the pH value of the reaction is 8-9, preferably 8.6. In some specific implementations, the reaction temperature is 15 ℃-35 ℃, preferably 20 ℃-30 ℃, and the time is 20 h-60 h, preferably 40 h-50 h. After the reaction is complete, the free platinum-containing drug is removed by dialysis in the dark to obtain the ultrasound-responsive nanomedicine.
[0076] The ultrasound-responsive nanomedicine provided in this application can be used to treat drug-resistant tumors, such as cisplatin-resistant lung cancer. After intravenous injection, the ultrasound-responsive nanomedicine provided in this application can rapidly accumulate in tumor tissue and be efficiently taken up by cancer cells due to its high permeability and retention effect (EPR effect). Upon reaching the lesion, the therapeutic dose of ultrasound acts as a "space-time switch," instantaneously triggering the disintegration of the nanocomposite and the targeted release of ferrous ions; the ferrous ions catalyze a cascade Fenton reaction, initiating a reactive oxygen species (ROS) storm. The ROS storm first severely damages mitochondria—mitochondrial network fragmentation, decreased membrane potential (ΔΨm), and energy metabolism breakdown; simultaneously, intracellular glutathione (GSH) is massively depleted, and lipid peroxides (LPO) surge. GSH depletion inhibits glutathione peroxidase 4 (GPX4) expression, while LPO accumulation directly initiates ferroptosis. With continued ultrasound, the nanomedicine completely disintegrates, releasing active platinum-based drugs; these platinum-based drugs rapidly cross-link with DNA, locking the cell cycle in the G1 phase and activating the apoptosis pathway. At the same time, ROS and DNA damage signals synergistically amplify autophagy, forming a synergistic mechanism of ferroptosis-apoptosis-autophagy, which enables precise and efficient elimination of tumor cells.
[0077] The ultrasound-responsive nanomedicine provided in this application comprises a copolymer of formula (I) and a platinum-containing drug. It exhibits ultrasound responsiveness, capable of directionally releasing ferrous ions under ultrasound. These ferrous ions catalyze a cascade Fenton reaction, triggering a ROS storm and forming a synergistic mechanism of ferroptosis-apoptosis-autophagy. Experimental results show that the ultrasound-responsive nanomedicine EG-PKF provided in this application… i Pt, under conditions simulating the tumor tissue microenvironment, achieves precise and efficient removal of tumor cells without affecting normal tissues. Attached Figure Description
[0078] Figure 1 Treatment of ferrocene cations (Fc) with ferrocene formate solution in H2O2 solution for different durations + The wavelength-absorbance curve of )
[0079] Figure 2 The absorbance curve of ferrocene formate solution after direct ultrasonic treatment at 630 nm;
[0080] Figure 3 The absorbance curve of ferrocene formate solution in H2O2 solution without ultrasonic treatment is shown at 630 nm.
[0081] Figure 4 The absorbance curve of ferrocene formate solution after ultrasonic treatment in H2O2 solution at 630 nm;
[0082] Figure 5Treatment of ferrocene formate solution with H2O2 solution for different durations of ferrous ions (Fe2+) 2+ The wavelength-absorbance curve of )
[0083] Figure 6 Direct ultrasonic treatment of ferrocene formate solution to remove ferrous ions (Fe2+) 2+ The absorbance curve of )
[0084] Figure 7 The absorbance curve of ferrocene formate solution in H2O2 solution without ultrasonic treatment is shown at 510 nm.
[0085] Figure 8 Sonication of ferrocene formate solution in H2O2 solution to remove ferrous ions (Fe2+) 2+ The absorbance curve of )
[0086] Figure 9 Three nano-assemblies EG-K prepared for the embodiments of this application Fci K SA The proton NMR spectrum;
[0087] Figure 10 Three nano-assemblies EG-K prepared for the embodiments of this application Fci K SA Fe 2+ Release curve;
[0088] Figure 11 Three nano-assemblies EG-K prepared for the embodiments of this application Fci K SA The ·OH generation curve;
[0089] Figure 12 Three nano-assemblies EG-K prepared for the embodiments of this application Fci K SA GSH consumption curve;
[0090] Figure 13 EG-K is a nano-assembly with 20 lysine residues. Fc10 K SA / CDDP morphology transmission electron microscope image;
[0091] Figure 14 EG-K is a nano-assembly with 30 lysine residues. Fc15 K SA / CDDP morphology transmission electron microscope image;
[0092] Figure 15 EG-K is a nano-assembly with 40 lysine residues. Fc20 K SA / CDDP morphology transmission electron microscope image;
[0093] Figure 16 EG-K is a nano-assembly with 20 lysine residues. Fc10 K SA / CDDP particle size distribution diagram;
[0094] Figure 17 EG-K is a nano-assembly with 30 lysine residues. Fc15 K SA / CDDP particle size distribution diagram;
[0095] Figure 18 EG-K is a nano-assembly with 40 lysine residues. Fc20 K SA / CDDP particle size distribution diagram;
[0096] Figure 19 EG-K nanoassemblies under different in vitro conditions Fc20 K SA / CDDP iron and platinum ion release status;
[0097] Figure 20 For different nano-assemblies EG-K Fci K SA / CDDP cytotoxicity to A549 or A549DDP cells under ultrasound conditions;
[0098] Figure 21 To analyze and test the level of ROS induced in tumor cells under different stimulation conditions using flow cytometry;
[0099] Figure 22 To analyze the level of hydroxyl radicals induced in tumor cells under different stimulation conditions using flow cytometry;
[0100] Figure 23 To analyze and test the level of tumor cell apoptosis induced under different stimulation conditions using flow cytometry;
[0101] Figure 24 The inhibition of tumor volume in cisplatin-resistant A549DDP under different administration conditions;
[0102] Figure 25 To investigate the inhibition of cisplatin-resistant A549DDP tumor quality under different administration conditions;
[0103] Figure 26 The effects of different drug administration conditions on liver function in mice;
[0104] Figure 27 The effects of different drug administration conditions on renal function in mice. Detailed Implementation
[0105] It should be understood that the expression “one or more of…” individually includes each of the objects described after the expression, as well as various different combinations of two or more of the described objects, unless otherwise understood from the context and usage. The expression “and / or” combined with three or more described objects should be understood to have the same meaning, unless otherwise understood from the context.
[0106] The terms “including,” “having,” or “containing,” including the use of their grammatical synonyms, should generally be understood as open-ended and non-restrictive, for example, not excluding other unstated elements or steps, unless otherwise specifically stated or understood from the context.
[0107] It should be understood that the order of steps or the sequence of actions is not important as long as this application remains operational. Furthermore, two or more steps or actions can be performed simultaneously.
[0108] The use of any and all instances or exemplary language such as “e.g.” or “including” herein is merely intended to better illustrate the application and does not constitute a limitation on the scope of the application unless the claims are made. No language in this specification should be construed as indicating that any unclaimed element is essential to the practice of this application.
[0109] Furthermore, the numerical ranges and parameters used to define this application are approximate values, and the relevant values in the specific embodiments have been presented as precisely as possible. However, any numerical value inevitably contains standard deviations due to individual test methods. Therefore, unless otherwise explicitly stated, it should be understood that all ranges, quantities, values, and percentages used in this disclosure are modified with the word "approximately." Here, "approximately" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a specific value or range.
[0110] This application provides a copolymer of formula (I):
[0111] Formula (I);
[0112] In equation (I), R1 is or R2 is or R3 represents H, CH3, , , , , or ;
[0113] q, r, and s are independently selected from integers from 1 to 4;
[0114] n and m are the degree of polymerization;
[0115] x+y+z=m, 0<x<m, 0<y<m, 0≤z<m.
[0116] The copolymer provided in this application contains ferrocene side chains, exhibiting ultrasonic responsiveness. Under ultrasonic stimulation, these chains break down and release ferrous ions. These ferrous ions catalyze a cascade Fenton reaction, triggering a reactive oxygen species (ROS) storm. The ROS storm first severely damages mitochondria—the mitochondrial network fragments, membrane potential (ΔΨm) decreases, and energy metabolism collapses. Simultaneously, intracellular glutathione (GSH) is massively depleted, and lipid peroxides (LPO) surge. GSH depletion inhibits glutathione peroxidase 4 (GPX4) expression, while LPO accumulation directly initiates ferroptosis, thereby killing tumor cells and treating tumors.
[0117] This application also provides a method for preparing copolymers having the structure of formula (I-1):
[0118] The amino-terminated polyethylene glycol and lysine N-carboxylic anhydride were subjected to a ring-opening polymerization reaction to obtain polyethylene glycol monomethyl ether-b-polylysine.
[0119] Ferrocene formate and polyethylene glycol monomethyl ether-b-polylysine were grafted together to obtain an intermediate product.
[0120] The succinic anhydride and the intermediate product were reacted to obtain a copolymer.
[0121] This application also provides an ultrasonically responsive nanocomposite material, comprising: a copolymer of formula (I) and a platinum-containing drug;
[0122] Formula (I);
[0123] In equation (I), R1 is or R2 is or R3 represents H, CH3, , , , , or ;
[0124] q, r, and s are independently selected from integers from 1 to 4;
[0125] n and m are the degree of polymerization;
[0126] x+y+z=m, 0<x<m, 0<y<m, 0≤z<m.
[0127] In the ultrasound-responsive nanocomposite material provided in this application, the copolymer shown in Formula (I) contains ferrocene side chains, exhibiting ultrasound responsiveness. Under ultrasound, these chains break and directionally release ferrous ions. The ferrous ions catalyze a cascade Fenton reaction, triggering a reactive oxygen species (ROS) storm. The ROS storm first severely damages mitochondria—the mitochondrial network fragments, membrane potential (ΔΨm) decreases, and energy metabolism collapses. Simultaneously, intracellular glutathione (GSH) is massively depleted, and lipid peroxides (LPO) surge. GSH depletion inhibits glutathione peroxidase 4 (GPX4) expression, while LPO accumulation directly initiates ferroptosis. Simultaneous downregulation of P-glycoprotein (P-gp) disrupts cisplatin efflux pathways, significantly reversing drug resistance. Furthermore, with continued ultrasound, the polymer completely disintegrates, releasing active cisplatin. Cisplatin rapidly cross-links with DNA, locking the cell cycle in the G1 phase and activating the apoptosis pathway. At the same time, ROS and DNA damage signals synergistically amplify autophagy, forming a triple attack network of ferroptosis-apoptosis-autophagy, achieving precise and efficient elimination of drug-resistant tumor cells.
[0128] This application also provides a method for preparing an ultrasonically responsive nanocomposite material, comprising the following steps:
[0129] A copolymer having the structure of formula (I) was subjected to a coordination reaction with a platinum-containing drug to obtain an ultrasonically responsive nanocomposite material.
[0130] Formula (I);
[0131] In equation (I), R1 is or R2 is or R3 represents H, CH3, , , , , or ;
[0132] q, r, and s are independently selected from integers from 1 to 4;
[0133] n and m are the degree of polymerization;
[0134] x+y+z=m, 0<x<m, 0<y<m, 0≤z<m.
[0135] The ultrasound-responsive nanocomposite material provided in this application comprises a copolymer as shown in formula (I) and a platinum-containing drug. It exhibits ultrasound responsiveness, enabling the directed release of ferrous ions under ultrasound. These ferrous ions catalyze a cascade Fenton reaction, triggering a ROS storm and forming a synergistic mechanism of ferroptosis-apoptosis-autophagy. Experimental results show that the ultrasound-responsive nanomedicine PFcPt provided in this application achieves precise and efficient removal of tumor cells under simulated tumor tissue microenvironment conditions, without affecting normal tissues.
[0136] The present application is further illustrated below with reference to embodiments. The scope of protection of the present application is not limited to the following embodiments.
[0137] Example 1 Synthesis of polylysine with different degrees of polymerization initiated by mPEG-NH2 (where the number of lysine residues is 20, 30, and 40).
[0138] Weigh the fully amino-terminated mPEG-NH2 (M w =5000 g·mol -1 4.9 g of the product was added to a vacuum reaction flask with a side arm. 400.0 mL of anhydrous toluene was added, and the mixture was heated in an oil bath at 128 °C while undergoing azeotropic dehydration. The azeotropic process lasted for 2 h to ensure complete removal of water from the system. Subsequently, residual toluene was removed by vacuum distillation to obtain dried amino-terminated mPEG-NH2. Next, 100.0 mL of anhydrous DMF was added through the side arm to fully dissolve the mPEG-NH2 and form a homogeneous solution. Then, under nitrogen protection, 17.9 g of Cbz-Lys NCA monomer was slowly added, and the system temperature was maintained at 25 °C. The mixture was stirred for 3 days to promote the ring-opening polymerization of the amino group and the NCA monomer. After the reaction was complete, the resulting polymer solution was slowly added dropwise to 8 to 10 times its volume of ice-cold diethyl ether to allow the product to precipitate. The precipitated solid was collected by centrifugation, and residual diethyl ether solvent was removed using a vacuum drying pump. The final product obtained is a white solid product—polyethylene glycol monomethyl ether-b-poly(N-benzyloxycarbonyl-lysine) (mPEG-bP(Cbz-Lys)).
[0139] Next, to obtain deprotected polylysine, 10.0 g of mPEG-bP (Cbz-Lys) was weighed and added to 100.0 mL of TFA, allowing it to dissolve completely to form a homogeneous solution. Subsequently, 30.0 mL of 33 wt.% HBr / AcOH was slowly added to this solution, and the mixture was stirred at room temperature for 2 h to completely remove the protecting groups. After the reaction was terminated, the mixture was slowly added dropwise to pre-cooled diethyl ether (300.0 mL) to induce product precipitation. The precipitate was collected by centrifugation, and the crude product was redissolved in DMF and transferred to a dialysis bag with MWCO = 3500 Da. Dialysis was performed for 72 h to remove small molecule byproducts. Finally, the dialysis solution was freeze-dried to obtain a white powder of polyethylene glycol monomethyl ether-b-polylysine (mPEG-b-PLys).
[0140] Example 2 Ferrocene (Fc)-grafted carboxylated polylysine (EG-K) Fci K S )synthesis
[0141] Taking a polymer with 40 lysine residues as an example, 1.0 g of mPEG-b-PLys and 0.24 g of commercially available ferrocene formate (CasNo: 2171-42-7) were dissolved in 15.0 mL of anhydrous DMF. 0.26 g of DMAP was dissolved in 3.0 mL of anhydrous DMF and added to the reaction solution. Finally, in an ice-water bath, 0.26 g of DIC was diluted with 5.0 mL of anhydrous DMF and slowly added dropwise to the reaction solution under a N2 atmosphere. After returning to room temperature, the reaction was allowed to proceed for 2 days. The reaction solution was then added dropwise to ice-cold diethyl ether to allow precipitation. The resulting white precipitate was dried under vacuum, reconstituted with DMF, placed in a dialysis bag with an MWCO = 3500 Da, and dialyzed against deionized water for 3 days. Finally, it was freeze-dried to obtain a yellow solid.
[0142] Weigh 1.0 g of the above yellow solid into 5.0 mL of pure water, and adjust the pH to 8.6 using 1.0 M NaOH aqueous solution. Then, add twice the amount of succinic anhydride, and maintain the pH in the range of 8-9 using 1.0 M NaOH. When the pH is constant, continue the reaction at room temperature for 8 h. After the reaction is complete, the yellow solid obtained after precipitation with ice-cold ether is the product.
[0143] Example 3: Nanoassembly EG-PKF i Synthesis of Pt
[0144] Nanoparticles were prepared using a nanoprecipitation method. In short, EG-PKF was first prepared by adding 1.0 mL of DMF. iH was dissolved and added dropwise to 3.0 mL of PBS solution over 1 hour using a constant flow pump. The solution was then dialyzed in PBS solution for 6 hours, with the PBS solution being changed every hour. Finally, the solution was concentrated by ultrafiltration and brought to a certain concentration with PBS solution.
[0145] Next, 1.0 mg of cisplatin was dissolved in the above nanoparticle solution, and the pH was adjusted to 8.6 with 1.0 M NaOH aqueous solution. After stabilization, the reaction was allowed to proceed for 48 hours, followed by dialysis in the dark to remove free cisplatin, yielding EG-K. Fci K SA / CDDP.
[0146] Nanoassemblies EG-K Fci K SA The preparation process of / CDDP is as follows:
[0147]
[0148] Example 4 Synthesis of triblock polymers of ferrocene-modified polylysine-phenylalanine materials initiated by mPEG-NH2 (where the number of lysines is 20, 30, or 40, and the number of phenylalanines is 5, 10, or 15).
[0149] Weigh the fully amino-terminated mPEG-NH2 (M w =5000 g·mol -1 4.9 g of the polymer solution was added to a vacuum reaction flask with a side arm. 400.0 mL of anhydrous toluene was added, and the mixture was heated in an oil bath at 128 °C while undergoing azeotropic dehydration. The azeotropic process lasted for 2 h to ensure complete removal of water from the system. Subsequently, residual toluene was removed by vacuum distillation to obtain dried amino-terminated mPEG-NH2. Next, 100.0 mL of anhydrous DMF was added through the side arm to fully dissolve the mPEG-NH2 and form a homogeneous solution. Then, under nitrogen protection, 17.9 g of Cbz-Lys NCA monomer was slowly added, and the system temperature was maintained at 25 °C. The mixture was stirred for 3 days to promote the ring-opening polymerization of the amino group and the NCA monomer. Next, under nitrogen protection, 1.9 g of phenylalanine NCA monomer was added, and the reaction continued for three days. After the reaction was complete, the resulting polymer solution was slowly added dropwise to 8 to 10 times its volume of ice-cold diethyl ether to allow the product to precipitate. The precipitated solid was collected by centrifugation, and residual diethyl ether solvent was removed using a vacuum drying pump. The final product obtained is a white solid product—polyethylene glycol monomethyl ether-b-poly(N-benzyloxycarbonyl-lysine)-b-polyphenylalanine (mPEG-bP(Cbz-Lys)-b-PPhe).
[0150] Next, to obtain the deprotected polyamino acid material, 10.0 g of mPEG-bP(Cbz-Lys)-b-PPhe was weighed and added to 100.0 mL of TFA, allowing it to dissolve completely to form a homogeneous solution. Subsequently, 30.0 mL of 33 wt.% HBr / AcOH was slowly added to the solution, and the mixture was stirred at room temperature for 2 h to completely remove the protecting groups. After the reaction was terminated, the mixture was slowly added dropwise to pre-cooled diethyl ether (300.0 mL) to induce product precipitation. The precipitate was collected by centrifugation, and the crude product was redissolved in DMF and transferred to a dialysis bag with MWCO = 3500 Da. Dialysis was performed for 72 h to remove small molecule byproducts. Finally, the dialysis solution was freeze-dried to obtain a white powder of polyethylene glycol monomethyl ether-b-polylysine-b-polyphenylalanine (mPEG-b-PLys-b-PPhe).
[0151] Taking a polymer with 40 lysine residues as an example, 1.0 g of mPEG-b-PLys-b-PPhe and 0.24 g of commercially available ferrocene formate (CasNo: 2171-42-7) were dissolved in 15.0 mL of anhydrous DMF. 0.26 g of DMAP was dissolved in 3.0 mL of anhydrous DMF and added to the reaction solution. Finally, in an ice-water bath, 0.26 g of DIC was diluted with 5.0 mL of anhydrous DMF and slowly added dropwise to the reaction solution under a N2 atmosphere. After returning to room temperature, the reaction was allowed to proceed for 2 days. The reaction solution was then added dropwise to ice-cold diethyl ether to settle. The resulting white precipitate was dried under vacuum, reconstituted with DMF, placed in a dialysis bag with an MWCO = 3500 Da, and dialyzed against deionized water for 3 days. Finally, the precipitate was freeze-dried to obtain a yellow solid.
[0152] Experimental Example 1
[0153] Ferrocene formate was dissolved in water to form a concentration of 200 μmol / L. −1 A solution with a pH of 5.5; ferrocene formate solution mixed with 100 μmol / L −1 The H2O2 solution was mixed and heated at 1 MHz and 1.5 W cm⁻¹. −2 Ultrasonic treatment was performed under the specified conditions, and the results are shown in [reference needed]. Figure 1 , Figure 2 , Figure 3 , Figure 4 , Figure 5 , Figure 6 , Figure 7 and Figure 8 ,in, Figure 1 The wavelength-absorbance curves are shown for ferrocene (Fc) treated with ferrocene formate solution in H2O2 solution for different durations. Figure 2The absorbance curve of ferrocene formate solution after direct ultrasonic treatment at 630 nm is shown. Figure 3 The absorbance curve of ferrocene formate solution in H2O2 solution without ultrasonic treatment is shown at 630 nm. Figure 4 The absorbance curve of ferrocene formate solution after ultrasonic treatment in H2O2 solution at 630 nm is shown. Figure 5 Treatment of ferrocene formate solution with H2O2 solution for different durations of ferrous ions (Fe2+) 2+ The wavelength-absorbance curve of ) Figure 6 Direct ultrasonic treatment of ferrocene formate solution to remove ferrous ions (Fe2+) 2+ The absorbance curve of ) Figure 7 The absorbance curve of ferrocene formate solution in H2O2 solution without ultrasonic treatment is shown at 510 nm. Figure 8 Sonication of ferrocene formate solution in H2O2 solution to remove ferrous ions (Fe2+) 2+ The absorbance curve of ( ). (From) Figures 1-8 It is known that under simulated tumor tissue microenvironment conditions, ferrocene formate can be accelerated to disintegrate under ultrasound to produce ferrocene formate cations, followed by the release of ferrous ions and the generation of hydroxyl radicals. The mechanism is as follows:
[0154]
[0155]
[0156] Experimental Example 2
[0157] The nanoassemblies EG-K prepared in Example 2 Fci K SA Nuclear magnetic resonance characterization was performed, and the results are shown in [reference needed]. Figure 9 , Figure 9 The nano-assembly EG-K prepared for the embodiments of this application Fci K SA The proton NMR spectrum.
[0158] The nanoassemblies EG-K prepared in Example 3 were tested using the corresponding kit method. Fci K SA / CDDP for Fe 2+ The results of tests on release, ·OH generation, and GSH consumption are as follows: Figure 10 , Figure 11 , Figure 12 As shown, Figure 10 Three nano-assemblies EG-K prepared for the embodiments of this application Fci K SA Fe 2+ Release curve; Figure 11Three nano-assemblies EG-K prepared for the embodiments of this application Fci K SA The ·OH generation curve; Figure 12 Three nano-assemblies EG-K prepared for the embodiments of this application Fci K SA The GSH consumption curve.
[0159] The nanoassembly EG-K prepared in Example 3 Fci K SA Morphological characterization was performed using / CDDP via transmission electron microscopy, and the results are shown in [link to documentation]. Figure 13 , Figure 14 and Figure 15 , Figure 13 EG-K is a nano-assembly with 20 lysine residues. Fc10 K SA / CDDP morphology transmission electron microscope image Figure 14 EG-K is a nano-assembly with 30 lysine residues. Fc15 K SA / CDDP morphology transmission electron microscope image Figure 15 EG-K is a nano-assembly with 40 lysine residues. Fc20 K SA / CDDP morphology transmission electron microscope image.
[0160] The nanoassemblies EG-K after the reaction of Example 3 with cisplatin were tested separately. Fci K SA For the particle size of / CDDP, see [see results]. Figure 16 , Figure 17 and Figure 18 , Figure 16 EG-K is a nano-assembly with 20 lysine residues. Fc10 K SA / CDDP particle size distribution diagram; Figure 17 EG-K is a nano-assembly with 30 lysine residues. Fc15 K SA / CDDP particle size distribution diagram; Figure 18 EG-K is a nano-assembly with 40 lysine residues. Fc20 K SA / CDDP particle size distribution diagram.
[0161] Depend on Figures 9-18 It can be seen that the nano-assemblies EG-PKF prepared in this application i Pt consists of nanoparticles with a particle size of 50~150nm.
[0162] The concentration of platinum was measured by inductively coupled plasma (ICP), and the drug loading rate of the nanoparticles was 20%.
[0163] Experiment Example 3: Metal Ion Release Experiment
[0164] Accurately weigh EG-K Fc20 K SA / CDDP was prepared into a stock solution with a concentration of 1 mg / mL and added to a dialysis bag. Different pH gradients were set in the dialysis bag. The sampling time was set according to the experimental requirements. After the time point, 2 mL of the external liquid was transferred to a centrifuge tube by pipette. Immediately, 2 mL of fresh release medium was added. 1 mL of the external liquid sample was taken and 2 mL of nitric acid (analytical grade) was added. The sample was digested at 100℃ for 30 minutes (or digested with a microwave digester). After cooling, the volume was adjusted with deionized water. The concentration of metal ions in the sample was detected by ICP-MS.
[0165] See results Figure 19 , Figure 19 A represents nanoassemblies EG-K under different in vitro conditions. Fc20 K SA / CDDP iron ion release status. Figure 19 B represents the nanoassemblies EG-K under different in vitro conditions. Fc20 K SA / CDDP platinum ion release. (By...) Figure 19 It is known that the nano-assembly EG-K provided in this application Fc20 K SA / CDDP can release iron and platinum ions under acidic and ultrasonic conditions.
[0166] Experimental Example 4: Drug Toxicity Test (MTT)
[0167] First, A549 / A549DDP cells were introduced at a rate of 5.0 × 10⁻⁶. 3 Inoculate each well with a culture medium and incubate overnight at 37 °C with 5% CO2 to allow adhesion. The next day, remove the old culture medium, wash twice with PBS, and then add culture media containing different materials at predetermined concentration gradients. Sonicate the sonicated groups at predetermined time points. After incubation to the end of the specified time, discard the culture medium, wash three times with PBS, add MTT solution to each well, dissolve in DMSO, and incubate at 37 °C for 30 min. Measure the absorbance at 490 nm using a microplate reader.
[0168] See results Figure 20 , Figure 20 For different nano-assemblies EG-PKF i Pt cytotoxicity against A549 or A549DDP cells under ultrasound conditions. Figure 20 It is known that, at the same drug concentration, the nano-assembly EG-K provided in this application... Fci K SABoth / CDDP can effectively inhibit tumor cell growth, and the polymer material with a degree of polymerization of 40 is EG-K. Fc20 K SA / CDDP showed the most significant inhibition effect.
[0169] Experimental Example 5
[0170] Intracellular ROS assay: One day in advance, cells were prepared at an appropriate density (e.g., 5 × 10⁶). 4 Cells (per well) were seeded into 6-well plates, and serum-containing medium was added. The plates were incubated at 37°C with 5% CO2 until 70%-80% confluence. After drug addition and sonication stimulation, the supernatant was discarded, and the cells were gently washed twice with pre-chilled PBS (avoiding vigorous pipetting to prevent cell damage). Cells were digested with 0.25% trypsin (approximately 1-2 min, stopping after observing cell rounding under a microscope), and serum-containing medium was added to neutralize the trypsin. A single-cell suspension was prepared by gentle pipetting. Diluted DCFH-DA probe was added, gently mixed, and incubated at 37°C with 5% CO2 in the dark for 20-30 min. After incubation, cells were washed twice with pre-chilled flow cytometry staining buffer (PBS containing 2% FBS) (1000 rpm, 5 min) to remove unconjugated probes, followed by flow cytometry evaluation.
[0171] Intracellular OH assay: One day in advance, cells are prepared at an appropriate density (e.g., 5 × 10⁶). 4 Cells (per well) were seeded into 6-well plates, and serum-containing medium was added. The plates were incubated at 37°C with 5% CO2 until 70%-80% confluence. After drug addition and sonication stimulation, the supernatant was discarded, and the cells were gently washed twice with pre-chilled PBS (avoiding vigorous pipetting to prevent cell damage). Cells were digested with 0.25% trypsin (approximately 1-2 min, stopping after observing cell rounding under a microscope). Serum-containing medium was added to neutralize the trypsin, and the cells were gently pipetted to prepare a single-cell suspension. Diluted BBoxiProbe probes were added, gently mixed, and incubated at 37°C with 5% CO2 in the dark for 20-30 min. After incubation, cells were washed twice with pre-chilled flow cytometry staining buffer (PBS containing 2% FBS) (1000 rpm, 5 min) to remove undeclared probes. The cells were then evaluated by flow cytometry.
[0172] Apoptosis assay: One day in advance, cells were prepared at an appropriate density (e.g., 5 × 10⁶ cells / day). 4Cells / well were seeded into 6-well plates, serum-containing medium was added, and the plates were incubated at 37 ℃ in a 5% CO2 incubator until 70%-80% confluence. After drug addition and sonication stimulation, the supernatant was discarded, and the cells were gently washed twice with pre-chilled PBS (avoiding vigorous pipetting to prevent cell damage). Cells were digested with 0.25% trypsin (approximately 1-2 min, stopping after observing cell rounding under a microscope), and the trypsin was neutralized with serum-containing medium. A single-cell suspension was prepared by gentle pipetting. Diluted Annexin V / PI probe was added, gently mixed, and incubated at 37 ℃ in a 5% CO2 incubator in the dark for 20-30 min. After incubation, the cells were washed twice with pre-chilled flow cytometry staining buffer (PBS containing 2% FBS) (1000 rpm, 5 min) to remove undeclared probes, followed by flow cytometry evaluation.
[0173] See results Figure 21 , Figure 22 and Figure 23 , Figure 21 To analyze and test the level of ROS induced in tumor cells under different stimulation conditions using flow cytometry, Figure 22 To analyze the levels of hydroxyl radicals induced in tumor cells under different stimulation conditions using flow cytometry, Figure 23 To analyze and test the level of apoptosis induced in tumor cells under different stimulation conditions using flow cytometry. Figure 21 , Figure 21 and Figure 23 It is known that the nano-assembly EG-PKF provided in this application 20 Under ultrasound conditions, Pt can significantly increase the level of ROS production and hydroxyl radical production in tumor cells, and induce tumor cell apoptosis.
[0174] Experiment Example 7: In vivo treatment experiment in animals
[0175] A subcutaneous cisplatin-resistant tumor model was established in BALB / c Nu nude mice by subcutaneously inoculating them with A549DDP cells. Tumor size was monitored during the process, reaching a maximum of 80 mm. 3 Mice were randomly divided into five groups on day 1. The groups were: PBS group, CDDP (cisplatin) group, and EG-K group. Fc20 K SA (Ferrocene-grafted carboxylated polylysine prepared in Example 2) + US (ultrasound), EG-K Fc20 K SA / CDDP (the nanoassembly EG-K prepared in Example 3) Fc20 K SA / CDDP) and EG-K Fc20 K SA / CDDP (the nanoassembly EG-K prepared in Example 3) Fc20 K SA Five groups of mice were administered Pt at a dose of 3 mg / kg (CDDP) + US (ultrasound). −1 The EG-K was injected into mice via the tail vein. Treatment was administered every two days for a total of four treatments. Twelve hours after injection, EG-K... Fc20 K SA / CDDP+US and EG-PKF 20 Pt+US was tested using ultrasound (1.0 MHz, 2.3 mW cm⁻¹). −2 In situ treatment for 5 minutes, tumor size and mouse weight were monitored, and the treatment effect is described in [reference needed]. Figure 24 and Figure 25 , Figure 24 To illustrate the inhibition of tumor volume in cisplatin-resistant A549DDP under different drug administration conditions, Figure 25 To investigate the inhibition of cisplatin-resistant A549DDP tumor quality under different administration conditions, [the following data was collected]. Figure 24 and Figure 25 It is understood that this application provides EG-K Fc20 K SA / CDDP drugs can significantly reduce the volume and weight of tumor cells under ultrasound conditions, and have a good therapeutic effect on tumors.
[0176] After the tumor suppression experiment, blood was collected and post-processed. Serum was separated and the effects of nanomedicine on the liver and kidneys of mice were evaluated. The results are shown in [link to results]. Figure 26 and Figure 27 , Figure 26 The effects of different drug administration conditions on liver function in mice were investigated. Figure 26 a is a bar chart of ALT levels in mouse serum. Figure 26 b is a bar chart of AST levels in mouse serum. Figure 27 The effects of different drug administration conditions on renal function in mice were investigated. Figure 27 a is a bar chart of BUN levels in mouse serum. Figure 27 b is a bar chart showing the CRE levels in mouse serum. Figure 26 and 27 It is known that the nano-assembly EG-PKF provided in this application 20 Pt has no side effects on the liver and kidneys of mice.
[0177] The above description is merely a preferred embodiment of this application, but the scope of protection of this application is not limited thereto. Any equivalent substitutions or modifications made by those skilled in the art within the scope of the technology disclosed in this application, based on the technical solution and inventive concept of this application, should be included within the scope of protection of this application.
Claims
1. An ultrasonically responsive nanocomposite material, characterized in that, include: The copolymer shown in formula (I) and platinum-containing drugs; Equation (I); In equation (I), R1 is or R2 is or R3 represents H, CH3, , , , , or ; q, r, s, and o are independently selected from integers from 1 to 4; n and m are the degree of polymerization; x+y+z=m, 0<x<m, 0<y<m, 0≤z<m.
2. The ultrasonically responsive nanocomposite material according to claim 1, characterized in that, R1 is R2 is ; z=0。 3. The ultrasonically responsive nanocomposite material according to claim 1, characterized in that, The m is selected from an integer between 10 and 100; The n is selected from an integer between 20 and 200; 0<x<2 / 3m, 0<y<2 / 3m, 0≤z<1 / 3m.
4. The ultrasonically responsive nanocomposite material according to claim 1, characterized in that, The platinum-containing drug coordinates with the carboxyl group of the copolymer shown in formula (I); The molar ratio of the carboxyl groups of the platinum-containing drug to the copolymer shown in formula (I) is 1:0.1~10; The platinum-based drugs are selected from one or more of cisplatin, carboplatin, oxaliplatin, transplatin, and nedaplatin.
5. The copolymer shown in formula (I): Equation (I); In equation (I), R1 is or R2 is or R3 represents H, CH3, , , , , or ; q, r, and s are independently selected from integers from 1 to 4; n and m are the degree of polymerization; x+y+z=m, 0<x<m, 0<y<m, 0≤z<m.
6. The copolymer according to claim 5, characterized in that, R1 is R2 is ; z=0。 7. The use of the ultrasonically responsive composite material according to any one of claims 1 to 4 or the copolymer according to claim 5 or 6 in the preparation of antitumor drugs.
8. The application according to claim 6, characterized in that, The tumor is lung cancer.
9. A method for preparing an ultrasonically responsive nanocomposite material, characterized in that, Includes the following steps: A copolymer having the structure of formula (I) was subjected to a coordination reaction with a platinum-containing drug to obtain an ultrasonically responsive nanocomposite material. Equation (I); In equation (I), R1 is or R2 is or R3 represents H, CH3, , , , , or ; q, r, and s are independently selected from integers from 1 to 4; n and m are the degree of polymerization; x+y+z=m, 0<x<m, 0<y<m, 0≤z<m.
10. The preparation method according to claim 9, characterized in that, R1 is R2 is ; z=0。
